New drug combo for T-cell lymphoma that returned or didn't respond
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for people with a type of lymphoma called T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help shrink tumors or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a type of T-cell lymphoma (including NK/T-cell lymphoma) that has returned or didn't respond to past treatment.
- You have at least one tumor that can be measured on a scan (like CT or PET).
- You are able to take care of yourself (ECOG score 0-2) and expected to live at least 3 more months.
- Your blood counts and organ function (liver, kidneys, thyroid) are within acceptable levels.
- You are not pregnant, breastfeeding, and agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.